Annual Results
Appendix 4E

Financial Year Ending 30 June 2022

CLINUVEL’s commercial operations are scaling up to meet treatment demand worldwide, while the Group is pursuing R&D projects which aim to add value over the long-term.

Our FY2022 results show a fundamentally strong business to date, allowing us to invest for future growth.

Mr Darren Keamy, Chief Financial Officer, CLINUVEL Group